PSP Research’s Ascendis Pharma A/S ASND Stock Holding History

PSP Research’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$400K	Sell	1,500 -1,000	-40%	-$234K	0.21%	34
2026 Q1	$572K	Sell	2,500 -79	-3%	-$17.7K	0.4%	6
2025 Q4	$550K	Buy	+2,579	New	+$533K	0.48%	10

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

PSP Research's ASND Position: Q2 2026 in Review

PSP Research reduced its Ascendis Pharma A/S (ASND) stake by 40% in Q2 2026, selling an estimated $234K and leaving 1,500 shares worth $400K. The position accounts for 0.21% of the portfolio, ranked #34.

PSP Research first reported a position in ASND in Q4 2025 and has held it in 3 quarters since. The position peaked at $572K in Q1 2026. 311 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

PSP Research held 1,500 shares of Ascendis Pharma A/S worth $400K as of Q2 2026.
PSP Research sold 1,000 Ascendis Pharma A/S shares in Q2 2026, an estimated $234K.
Ascendis Pharma A/S made up 0.21% of PSP Research's portfolio in Q2 2026, its #34 holding.
PSP Research first reported a position in Ascendis Pharma A/S in Q4 2025 and has held it in 3 quarters since.
PSP Research's Ascendis Pharma A/S position peaked at $572K in Q1 2026.
311 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on PSP Research's 13F filing for Q2 2026, filed 9 Jul 2026.